TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.
Brief Summary: The purpose of the study is to test whether Macugen injected into the eye improves vision in more patients than the currently existing standard of care laser therapy. The safety of Macugen compared to standard of care laser will also be evaluated.


Options:
A: Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: Laser with Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser with Ranibizumab, Ranibizumab | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): Laser, Laser with Ranibizumab
B: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser
C: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A
D: Arm Label: Sham Control; Type: SHAM_COMPARATOR; Interventions: Drug: Standard of Care | Arm Label: Macugen; Type: EXPERIMENTAL; Interventions: Drug: Macugen | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Sham Control | Intervention Type: DRUG; Name: Macugen; Assigned to Arm(s): Macugen

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label Randomised Controlled Study to Compare the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. Versus Epoetin Alfa for the Maintenance of Haemoglobin Levels in Hemodialysis Patients With Chronic Renal Anaemia
Brief Summary: This 2 arm study will compare the efficacy and safety of monthly administration of intravenous (IV) Mircera versus epoetin alfa for the maintenance of hemoglobin levels in hemodialysis patients with chronic renal anemia. Participants currently receiving maintenance treatment with epoetin alfa will be randomized either to receive monthly injections of 120, 200 or 360 micrograms Mircera, with the starting dose derived from the dose of epoetin alfa they were receiving in the week preceding study start, or to continue on epoetin alfa treatment. The anticipated duration of study is 32 weeks, and the target sample size is 146 participants.


Options:
A: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly
B: Arm Label: C.E.R.A; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta | Arm Label: Epoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): C.E.R.A | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Epoetin Alfa
C: Arm Label: RO0503821 (C.E.R.A.), 1x/4weeks; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (C.E.R.A.), 1x/4weeks
D: Arm Label: Mircera in Renal Anemia; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Mircera in Renal Anemia

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label Randomised Controlled Study to Compare the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous Mircera Versus Darboepoetin Alfa for the Maintenance of Haemoglobin Levels in Renal Transplant Recipients With Chronic Renal Anaemia.
Brief Summary: This two arm study will compare the efficacy and safety of subcutaneous Mircera versus darbepoetin alfa for the maintenance of hemoglobin levels in kidney transplant recipients with chronic renal anemia. Patients currently receiving maintenance treatment with darbepoetin alfa will be randomized either to receive 4-weekly injections of Mircera with a starting dose (120, 200 or 360 micrograms subcutaneously) derived from the dose of darbepoetin alfa they were receiving in the 2 weeks preceding study start, or to stay on 2-weekly darbepoetin alfa therapy. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
B: Arm Label: Group 1 (Early Epoetin Beta); Type: EXPERIMENTAL; Interventions: Drug: Epoetin beta | Arm Label: Group 2 (No/Late Epoetin Beta); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin beta | Intervention Type: DRUG; Name: Epoetin beta; Assigned to Arm(s): Group 1 (Early Epoetin Beta), Group 2 (No/Late Epoetin Beta)
C: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly
D: Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label Randomised Controlled Study to Compare the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous Mircera Versus Darboepoetin Alfa for the Maintenance of Haemoglobin Levels in Renal Transplant Recipients With Chronic Renal Anaemia.
Brief Summary: This two arm study will compare the efficacy and safety of subcutaneous Mircera versus darbepoetin alfa for the maintenance of hemoglobin levels in kidney transplant recipients with chronic renal anemia. Patients currently receiving maintenance treatment with darbepoetin alfa will be randomized either to receive 4-weekly injections of Mircera with a starting dose (120, 200 or 360 micrograms subcutaneously) derived from the dose of darbepoetin alfa they were receiving in the 2 weeks preceding study start, or to stay on 2-weekly darbepoetin alfa therapy. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo (Epoetin delta) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dynepo | Intervention Type: DRUG; Name: Dynepo (Epoetin delta); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dynepo; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): 1
D: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label Randomised Controlled Study to Compare the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous Mircera Versus Darboepoetin Alfa for the Maintenance of Haemoglobin Levels in Renal Transplant Recipients With Chronic Renal Anaemia.
Brief Summary: This two arm study will compare the efficacy and safety of subcutaneous Mircera versus darbepoetin alfa for the maintenance of hemoglobin levels in kidney transplant recipients with chronic renal anemia. Patients currently receiving maintenance treatment with darbepoetin alfa will be randomized either to receive 4-weekly injections of Mircera with a starting dose (120, 200 or 360 micrograms subcutaneously) derived from the dose of darbepoetin alfa they were receiving in the 2 weeks preceding study start, or to stay on 2-weekly darbepoetin alfa therapy. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Peginesatide 0.025 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Peginesatide 0.04 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.025 mg/kg | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.04 mg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
B: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly
C: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
D: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Subject and Evaluator Blinded, Sham Controlled, Multicenter Study to Evaluate Efficacy and Safety of NASHA/Dx for the Treatment of Fecal Incontinence
Brief Summary: The purpose of this study is to determine the effectiveness and safety of NASHA/Dx when used as an injectable bulking agent in the treatment of fecal incontinence. The study includes a 6-month blinded sham-controlled phase, followed by an open-label phase.


Options:
A: Arm Label: Sensory threshold - Amplitude; Type: ACTIVE_COMPARATOR; Interventions: Device: Sensory Threshold | Arm Label: 25% below sensory threshold - Amplitude; Type: EXPERIMENTAL; Interventions: Device: 75% of sensory threshold - Amplitude | Arm Label: 50% below sensory threshold - Amplitude; Type: EXPERIMENTAL; Interventions: Device: 50% of sensory threshold - Amplitude | Intervention Type: DEVICE; Name: Sensory Threshold; Assigned to Arm(s): Sensory threshold - Amplitude | Intervention Type: DEVICE; Name: 75% of sensory threshold - Amplitude; Assigned to Arm(s): 25% below sensory threshold - Amplitude | Intervention Type: DEVICE; Name: 50% of sensory threshold - Amplitude; Assigned to Arm(s): 50% below sensory threshold - Amplitude
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 2
C: Arm Label: InterStim therapy; Type: EXPERIMENTAL; Interventions: Device: Type: Implantable neurostimulator; InterStim | Intervention Type: DEVICE; Name: Type: Implantable neurostimulator; InterStim; Assigned to Arm(s): InterStim therapy
D: Arm Label: Blinded injection of NASHA/Dx gel at randomization.; Type: EXPERIMENTAL; Interventions: Device: NASHA/Dx (Solesta) Gel | Arm Label: Blinded sham inject. at randomization; Type: SHAM_COMPARATOR; Interventions: Device: Sham Injection | Arm Label: Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.; Type: OTHER; Interventions: Device: NASHA/Dx (Solesta) Gel, Device: Sham Injection | Intervention Type: DEVICE; Name: NASHA/Dx (Solesta) Gel; Assigned to Arm(s): Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo., Blinded injection of NASHA/Dx gel at randomization. | Intervention Type: DEVICE; Name: Sham Injection; Assigned to Arm(s): Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo., Blinded sham inject. at randomization

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
Brief Summary: This study will test the ability of the topical cream WR 279,396 to treat the skin lesions caused by the parasite called leishmania. WR 279,396 is an antibiotic preparation that contains paromomycin + gentamicin. This cream will be compared to the effect of a topical cream containing paromomycin alone and to a placebo cream that contains no antibiotics. Therefore, this study will have three groups of patients, and they will be assigned to one of these treatments randomly. The study will be carried out without the patient or the physician knowing which cream is being used for which patient. The goal is to determine if WR 279,396 cream or the paromomycin cream is better than placebo, and if WR 279,396 is better than paromomycin alone.


Options:
A: Arm Label: WR 279,396 Topical Treament; Type: EXPERIMENTAL; Interventions: Drug: WR 279,396 topical cream | Arm Label: Paromomycin Alone Topical treatment; Type: EXPERIMENTAL; Interventions: Drug: Paromomycin Alone topical cream | Arm Label: Vehicle Placebo Cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle placebo cream | Intervention Type: DRUG; Name: WR 279,396 topical cream; Assigned to Arm(s): WR 279,396 Topical Treament | Intervention Type: DRUG; Name: Paromomycin Alone topical cream; Assigned to Arm(s): Paromomycin Alone Topical treatment | Intervention Type: DRUG; Name: Vehicle placebo cream; Assigned to Arm(s): Vehicle Placebo Cream
B: Intervention Type: DRUG; Name: Amphotericin B deoxycholate given as daily administration; Assigned to Arm(s): N/A
C: Arm Label: WR 279,396; Type: EXPERIMENTAL; Interventions: Drug: WR 279,396 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: WR 279,396; Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: IL SSG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium Stibogluconate | Arm Label: ETC+MWT; Type: EXPERIMENTAL; Interventions: Procedure: Electro-thermo-coagulation, Drug: DAC N-055 | Arm Label: MWT; Type: EXPERIMENTAL; Interventions: Drug: DAC N-055 | Intervention Type: PROCEDURE; Name: Electro-thermo-coagulation; Assigned to Arm(s): ETC+MWT | Intervention Type: DRUG; Name: Sodium Stibogluconate; Assigned to Arm(s): IL SSG | Intervention Type: DRUG; Name: DAC N-055; Assigned to Arm(s): ETC+MWT, MWT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
Brief Summary: This study will test the ability of the topical cream WR 279,396 to treat the skin lesions caused by the parasite called leishmania. WR 279,396 is an antibiotic preparation that contains paromomycin + gentamicin. This cream will be compared to the effect of a topical cream containing paromomycin alone and to a placebo cream that contains no antibiotics. Therefore, this study will have three groups of patients, and they will be assigned to one of these treatments randomly. The study will be carried out without the patient or the physician knowing which cream is being used for which patient. The goal is to determine if WR 279,396 cream or the paromomycin cream is better than placebo, and if WR 279,396 is better than paromomycin alone.


Options:
A: Arm Label: Sodium stibogluconate intravenous; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium stibogluconate (Pentostam) | Arm Label: ThermoMed device; Type: EXPERIMENTAL; Interventions: Device: ThermoMed | Intervention Type: DRUG; Name: Sodium stibogluconate (Pentostam); Assigned to Arm(s): Sodium stibogluconate intravenous | Intervention Type: DEVICE; Name: ThermoMed; Assigned to Arm(s): ThermoMed device
B: Intervention Type: DRUG; Name: Amphotericin B deoxycholate given as daily administration; Assigned to Arm(s): N/A
C: Arm Label: WR 279,396 Topical Treament; Type: EXPERIMENTAL; Interventions: Drug: WR 279,396 topical cream | Arm Label: Paromomycin Alone Topical treatment; Type: EXPERIMENTAL; Interventions: Drug: Paromomycin Alone topical cream | Arm Label: Vehicle Placebo Cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle placebo cream | Intervention Type: DRUG; Name: WR 279,396 topical cream; Assigned to Arm(s): WR 279,396 Topical Treament | Intervention Type: DRUG; Name: Paromomycin Alone topical cream; Assigned to Arm(s): Paromomycin Alone Topical treatment | Intervention Type: DRUG; Name: Vehicle placebo cream; Assigned to Arm(s): Vehicle Placebo Cream
D: Intervention Type: DRUG; Name: Paromomycin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amphotericin B; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial
Brief Summary: Recurrent miscarriage is a prevalent reproductive problem that affects many couples who are trying to establish a family. This clinical study will evaluate the effectiveness of intravenous immunoglobulin (IVIG) in improving the live birth rate in couples who suffer from secondary recurrent miscarriage. This study will help in providing an answer to the question of whether IVIG is helpful in secondary recurrent miscarriage.


Options:
A: Arm Label: LMWH + Folic acid group; Type: EXPERIMENTAL; Interventions: Drug: LMWH+Folic acid | Arm Label: Folic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Folic Acid | Intervention Type: DRUG; Name: LMWH+Folic acid; Assigned to Arm(s): LMWH + Folic acid group | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Folic acid
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gamimune N or Gamunex 10% | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Intervention Type: BIOLOGICAL; Name: Gamimune N or Gamunex 10%; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): 2
C: Arm Label: enoxaparin 40 mg plus low dose aspirin; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin 40mg plus low dose aspirin | Arm Label: Heparin calcium 5,000 U twice daily plus low dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin calcium5,000 U twice daily plus low dose aspirin | Intervention Type: DRUG; Name: enoxaparin 40mg plus low dose aspirin; Assigned to Arm(s): enoxaparin 40 mg plus low dose aspirin | Intervention Type: DRUG; Name: Heparin calcium5,000 U twice daily plus low dose aspirin; Assigned to Arm(s): Heparin calcium 5,000 U twice daily plus low dose aspirin
D: Arm Label: Enoxaparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Warfarin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin group | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin group

Answer: B